{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:01:55Z","timestamp":1784523715476,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162216"],"award-info":[{"award-number":["PJT-162216"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2019-06467"],"award-info":[{"award-number":["RGPIN-2019-06467"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computer Methods and Programs in Biomedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cmpb.2023.108004","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T09:45:56Z","timestamp":1704102356000},"page":"108004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177Lu-PSMA therapy of prostate cancer"],"prefix":"10.1016","volume":"245","author":[{"given":"Anahita","family":"Piranfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad M.","family":"Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos F.","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"3","key":"10.1016\/j.cmpb.2023.108004_bib0002","first-page":"312","article-title":"Is 177 Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?","volume":"23","author":"Gupta","year":"2020","journal-title":"Hell. J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.cmpb.2023.108004_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"issue":"12","key":"10.1016\/j.cmpb.2023.108004_bib0004","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu] Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","author":"Rosar","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.cmpb.2023.108004_bib0005","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177 Lu-labelled PSMA-ligands (177 Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.cmpb.2023.108004_bib0007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"de Feria Cardet","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-022-01050-3","article-title":"Pre-and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy","volume":"22","author":"Wrenger","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.cmpb.2023.108004_bib0009","doi-asserted-by":"crossref","first-page":"835956","DOI":"10.3389\/fonc.2022.835956","article-title":"177Lu-PSMA-I&T radioligand therapy for treating metastatic castration-resistant prostate cancer: a single-centre study in East Asians","volume":"12","author":"Bu","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.cmpb.2023.108004_bib0010","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu] Lu-PSMA I&T and [177Lu] Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.cmpb.2023.108004_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221081922","article-title":"Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review","volume":"14","author":"Heidegger","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cmpb.2023.108004_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2022.940677","article-title":"Towards routine clinical use of dosimetry in [177Lu] Lu-PSMA prostate cancer radionuclide therapy: current efforts and future perspectives","volume":"10","author":"Alsadi","year":"2022","journal-title":"Front. Phys."},{"issue":"3","key":"10.1016\/j.cmpb.2023.108004_bib0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12149-018-1230-7","article-title":"Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy","volume":"32","author":"Hosono","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.cmpb.2023.108004_bib0014","unstructured":"Crestoni M.E. Radiopharmaceuticals for diagnosis and therapy. 2018."},{"key":"10.1016\/j.cmpb.2023.108004_bib0015","series-title":"Seminars in Nuclear Medicine","article-title":"Therapeutic radionuclides: biophysical and radiobiologic principles","author":"Kassis","year":"2008"},{"issue":"12","key":"10.1016\/j.cmpb.2023.108004_bib0016","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.cmpb.2023.108004_bib0017","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1073\/pnas.1700340114","article-title":"Role of vascular normalization in benefit from metronomic chemotherapy","volume":"114","author":"Mpekris","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.cmpb.2023.108004_bib0018","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2217\/nnm-2021-0126","article-title":"Drug delivery through nanoparticles in solid tumors: a mechanistic understanding","volume":"17","author":"Kashkooli","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cmpb.2023.108004_bib0019","article-title":"Computational modeling of drug delivery to solid tumors: a pilot study based on a real image","volume":"62","author":"Kashkooli","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.cmpb.2023.108004_bib0020","first-page":"1567","article-title":"PBPK-based histology-driven in silico tumor microenvironment model for PSMA-directed radioligand therapy","volume":"62","author":"Birindelli","year":"2021","journal-title":"Soc. Nucl. Med."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56603-8","article-title":"The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model","volume":"9","author":"Begum","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmpb.2023.108004_bib0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nucmedbio.2019.05.003","article-title":"Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands","volume":"72","author":"Winter","year":"2019","journal-title":"Nucl. Med. Biol."},{"issue":"14","key":"10.1016\/j.cmpb.2023.108004_bib0023","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.3390\/cancers13143429","article-title":"Is hypoxia a factor influencing PSMA-directed radioligand therapy?\u2013An in silico study on the role of chronic hypoxia in prostate cancer","volume":"13","author":"Birindelli","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.cmpb.2023.108004_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/pp-2017-0004","article-title":"Modelling drug transport during intraperitoneal chemotherapy","volume":"2","author":"Steuperaert","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"10.1016\/j.cmpb.2023.108004_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1559325820914189","article-title":"Dose-dependent internalization and externalization integrity study of newly synthesized 99mTc-thymoquinone radiopharmaceutical as cancer theranostic agent","volume":"18","author":"Tariq","year":"2020","journal-title":"Dose Response"},{"issue":"10","key":"10.1016\/j.cmpb.2023.108004_bib0026","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3390\/cells9102334","article-title":"Development of radiotracers for breast cancer\u2013the tumor microenvironment as an emerging target","volume":"9","author":"Heesch","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.cmpb.2023.108004_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides","volume":"11","author":"Kletting","year":"2016","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.cmpb.2023.108004_bib0028","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0026-2862(90)90023-K","article-title":"Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics","volume":"40","author":"Baxter","year":"1990","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.cmpb.2023.108004_bib0029","article-title":"Drug delivery to solid tumors with heterogeneous microvascular networks: novel insights from image-based numerical modeling","volume":"151","author":"Kashkooli","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-00989-x","article-title":"Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach","volume":"11","author":"Moradi Kashkooli","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmpb.2023.108004_bib0031","article-title":"Effect of vascular normalization on drug delivery to different stages of tumor progression: in-silico analysis","volume":"60","author":"Kashkooli","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-13345-4","article-title":"A spatiotemporal multi-scale computational model for FDG PET imaging at different stages of tumor growth and angiogenesis","volume":"12","author":"Kashkooli","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cmpb.2023.108004_bib0033","doi-asserted-by":"crossref","first-page":"e20344","DOI":"10.1371\/journal.pone.0020344","article-title":"Numerical modeling of fluid flow in solid tumors","volume":"6","author":"Soltani","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-98638-w","article-title":"Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors","volume":"11","author":"Soltani","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1754-1611-8-12","article-title":"Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors","volume":"8","author":"Sefidgar","year":"2014","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.cmpb.2023.108004_bib0036","series-title":"U-Th Series Nuclides in Aquatic Systems","first-page":"425","article-title":"Systematics of radioactive decay","author":"Krishnaswami","year":"2011"},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0037","first-page":"1","article-title":"Modelling of combination therapy using implantable anticancer drug delivery with thermal ablation in solid tumor","volume":"10","author":"Al-Zu'bi","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cmpb.2023.108004_bib0038","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/cancers12061452","article-title":"The mechanical microenvironment in breast cancer","volume":"12","author":"Pratt","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cmpb.2023.108004_bib0039","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for 177 Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.cmpb.2023.108004_bib0040","first-page":"2021","article-title":"In vivo evaluation of gallium-68-labeled IRDye800CW as a necrosis avid contrast agent in solid tumors","author":"Stroet","year":"2021","journal-title":"Contrast Media Mol. Imaging"},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trecan.2021.09.003","article-title":"Necroptosis and tumor progression","volume":"8","author":"Yan","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cmpb.2023.108004_bib0042","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.cmpb.2023.108004_bib0043","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/10717544.2016.1269848","article-title":"Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule","volume":"24","author":"Steuperaert","year":"2017","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.cmpb.2023.108004_bib0044","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure\u2013an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.cmpb.2023.108004_bib0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/09553009114551621","article-title":"Haemodynamic and transport barriers to the treatment of solid tumours","volume":"60","author":"Jain","year":"1991","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.cmpb.2023.108004_bib0046","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s10439-010-9957-x","article-title":"Poroviscoelastic modeling of liver biomechanical response in unconfined compression","volume":"38","author":"Raghunathan","year":"2010","journal-title":"Ann. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.cmpb.2023.108004_bib0047","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12149-016-1141-4","article-title":"Spatiotemporal distribution modeling of PET tracer uptake in solid tumors","volume":"31","author":"Soltani","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.cmpb.2023.108004_bib0048","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2020.11.011","article-title":"Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma","volume":"155","author":"Liang","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cmpb.2023.108004_bib0049","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-35727-6_6","article-title":"Necrosis in the tumor microenvironment and its role in cancer recurrence","author":"Karsch-Bluman","year":"2020","journal-title":"Tumor Microenviron."},{"key":"10.1016\/j.cmpb.2023.108004_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mvr.2015.06.007","article-title":"Numerical simulation of the tumor interstitial fluid transport: consideration of drug delivery mechanism","volume":"101","author":"Moghadam","year":"2015","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.cmpb.2023.108004_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2020.105606","article-title":"Numerical study of microwave induced thermoacoustic imaging for initial detection of cancer of breast on anatomically realistic breast phantom","volume":"196","author":"Rahpeima","year":"2020","journal-title":"Comput. Methods Programs Biomed."},{"issue":"6","key":"10.1016\/j.cmpb.2023.108004_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233219","article-title":"Use of microwave ablation for thermal treatment of solid tumors with different shapes and sizes\u2013a computational approach","volume":"15","author":"Tehrani","year":"2020","journal-title":"PLoS ONE"}],"container-title":["Computer Methods and Programs in Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260723006703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260723006703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:17:15Z","timestamp":1777515435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169260723006703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"alternative-id":["S0169260723006703"],"URL":"https:\/\/doi.org\/10.1016\/j.cmpb.2023.108004","relation":{},"ISSN":["0169-2607"],"issn-type":[{"value":"0169-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177Lu-PSMA therapy of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Computer Methods and Programs in Biomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmpb.2023.108004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108004"}}